Calidi Biotherapeutics, Inc. announced that it will receive $3,500,000 in funding on March 8, 2024. The company will issue convertible debt in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 USD | +10.55% |
|
+7.96% | -88.41% |
07-08 | Calidi Biotherapeutics, Inc. Enters into A Certain Loan Agreement with Dennis R. Conklin | CI |
07-05 | Calidi Biotherapeutics to Implement 1-For-10 Reverse Stock Split | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.41% | 11.23M | |
+20.63% | 127B | |
+25.04% | 27.67B | |
-20.17% | 20.33B | |
-17.08% | 16.79B | |
-18.07% | 15.63B | |
-47.70% | 14.65B | |
+11.92% | 14.84B | |
+58.32% | 14.43B | |
+149.98% | 12.49B |
- Stock Market
- Equities
- CLDI Stock
- News CALI BIOTPAR
- Calidi Biotherapeutics, Inc. announced that it expects to receive $3.5 million in funding